Epigenetic Alterations in Pancreatic Cancer

  • Michael Ayars
  • Michael Goggins


Pancreatic cancer remains one of the deadliest malignancies. In addition to genetic alterations a wide variety of epigenetic aberrations have been identified in pancreatic neoplasms some of which are thought to play an important role in neoplastic development and maintenance. Newer technologies are helping to better characterize cancer epigenomes. Efforts are underway to identify epigenetic alterations that would make optimal diagnostic markers and therapeutic targets. In this chapter, we discuss recent findings in the field of pancreatic cancer epigenetics and the implications they hold for future research.


Pancreatic Cancer Histone Modification Pancreatic Cancer Cell HDAC Inhibitor Pancreatic Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by NIH grants (CA62924, R01CA120432, and RC2CA148376), and the Michael Rolfe Foundation.


  1. Abbosh PH et al (2006) Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66(11):5582–5591PubMedGoogle Scholar
  2. Abe T et al (2005) Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 40(5):504–510PubMedGoogle Scholar
  3. Abele R et al (1987) The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23(12):1921–1924PubMedGoogle Scholar
  4. Aghdassi A et al (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61(3):439–448PubMedGoogle Scholar
  5. Akada M et al (2005) Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11(8):3094–3101PubMedGoogle Scholar
  6. Angst E et al (2010) Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells. Pancreas 39(5):675–679PubMedGoogle Scholar
  7. Arnold NB et al (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13(1):18–26PubMedGoogle Scholar
  8. Azmi AS et al (2011) Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics 3(6):747–759PubMedGoogle Scholar
  9. Ball MP et al (2009) Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 27(4):361–368PubMedGoogle Scholar
  10. Bao B et al (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72(1):335–345PubMedGoogle Scholar
  11. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734PubMedGoogle Scholar
  12. Bestor T et al (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203(4):971–983PubMedGoogle Scholar
  13. Biankin AV et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399–405PubMedGoogle Scholar
  14. Blumenschein GR Jr et al (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81–87PubMedGoogle Scholar
  15. Brune K et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30(9):1067–1076PubMedGoogle Scholar
  16. Byrd JC et al (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3):959–967PubMedGoogle Scholar
  17. Chan TA et al (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5(5):e114PubMedGoogle Scholar
  18. Chen RZ et al (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395(6697): 89–93PubMedGoogle Scholar
  19. Chien CH et al (2011) Identifying transcriptional start sites of human microRNAs based on high-­throughput sequencing data. Nucleic Acids Res 39(21):9345–9356PubMedGoogle Scholar
  20. Choi JH et al (2007) Site-specific methylation of CpG nucleotides in the hTERT promoter region can control the expression of hTERT during malignant progression of colorectal carcinoma. Biochem Biophys Res Commun 361(3):615–620PubMedGoogle Scholar
  21. Clark SJ (2007) Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 16(1):R88–R95PubMedGoogle Scholar
  22. Cui K et al (2009) Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 4(1):80–93PubMedGoogle Scholar
  23. Daniel M, Peek GW, Tollefsbol TO (2012) Regulation of the human catalytic subunit of telomerase (hTERT). Gene 498(2):135–146PubMedGoogle Scholar
  24. De Carvalho DD et al (2012) DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21(5):655–667PubMedGoogle Scholar
  25. de Wilde RF et al (2012) Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 25(7):1033–1039PubMedGoogle Scholar
  26. Dejeux E et al (2009) Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer 16(3):939–952PubMedGoogle Scholar
  27. Dessain SK et al (2000) Methylation of the human telomerase gene CpG island. Cancer Res 60(3):537–541PubMedGoogle Scholar
  28. Devereux TR et al (1999) DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 59(24):6087–6090PubMedGoogle Scholar
  29. Dialynas GK, Vitalini MW, Wallrath LL (2008) Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutat Res 647(1–2):13–20PubMedGoogle Scholar
  30. DiGiuseppe JA et al (1994) Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 144(5):889–895PubMedGoogle Scholar
  31. Dodge JE et al (2002) De novo methylation of MMLV provirus in embryonic stem cells: CpG versus non-CpG methylation. Gene 289(1–2):41–48PubMedGoogle Scholar
  32. Easwaran HP et al (2010) Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. Cancer Res 70(20):8015–8024PubMedGoogle Scholar
  33. Eden S et al (1998) DNA methylation models histone acetylation. Nature 394(6696):842PubMedGoogle Scholar
  34. Ellis L et al (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14(14):4500–4510PubMedGoogle Scholar
  35. Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16(1):R50–R59PubMedGoogle Scholar
  36. Federico A et al (2009) Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 69(17):7079–7087 Fitzgerald M, Oshiro M et al (2003) Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5(5):427–436PubMedGoogle Scholar
  37. Fujii S et al (2008) Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283(25):17324–17332PubMedGoogle Scholar
  38. Fukushima N et al (2003) Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89(2):338–343PubMedGoogle Scholar
  39. Gao J et al (2010) Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res 29:28PubMedGoogle Scholar
  40. Garcia-Manero G et al (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981–989PubMedGoogle Scholar
  41. Garcia-Morales P et al (2005) Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 4(8):1222–1230PubMedGoogle Scholar
  42. Gaudet F et al (2003) Induction of tumors in mice by genomic hypomethylation. Science 300(5618):489–492PubMedGoogle Scholar
  43. Giatromanolaki A et al (2004) BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 10(16):5566–5571PubMedGoogle Scholar
  44. Grady WM et al (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27(27):3880–3888PubMedGoogle Scholar
  45. Graff JR et al (2000) Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275(4):2727–2732PubMedGoogle Scholar
  46. Hahn MA et al (2011) Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PLoS One 6(4):e18844PubMedGoogle Scholar
  47. Hashimshony T et al (2003) The role of DNA methylation in setting up chromatin structure during development. Nat Genet 34(2):187–192PubMedGoogle Scholar
  48. He S et al (2011) Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PLoS One 6(11):e27684PubMedGoogle Scholar
  49. Hellman A, Chess A (2007) Gene body-specific methylation on the active X chromosome. Science 315(5815):1141–1143PubMedGoogle Scholar
  50. Hong SM et al (2011) Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol 24(9):1237–1247PubMedGoogle Scholar
  51. Hong SM et al (2012) Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 18(3):700–712 Iacobuzio-Donahue CA, Maitra A et al (2003) Exploration of global gene expression ­patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162(4):1151–1162PubMedGoogle Scholar
  52. Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15(12):3938–3946PubMedGoogle Scholar
  53. Jansen M et al (2002) Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 1(3):293–296PubMedGoogle Scholar
  54. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074–1080PubMedGoogle Scholar
  55. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692PubMedGoogle Scholar
  56. Jones PL et al (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19(2):187–191PubMedGoogle Scholar
  57. Jones S et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806PubMedGoogle Scholar
  58. Kanda M et al (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142(4):730.e9–733.e9Google Scholar
  59. Karamitopoulou E et al (2010) Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 46(8):1438–1444PubMedGoogle Scholar
  60. Kauffman EC et al (2011) Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in loc.lized and advanced human bladder cancer. Mol Carcinog 50(12):931–944PubMedGoogle Scholar
  61. Kelly TK et al (2010) H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell 39(6):901–911PubMedGoogle Scholar
  62. Klymkowsky MW, Savagner P (2009) Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 174(5):1588–1593PubMedGoogle Scholar
  63. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705PubMedGoogle Scholar
  64. Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-­sequencing data. Nucleic Acids Res 39(Database issue):D152–D157PubMedGoogle Scholar
  65. Ku M et al (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4(10):e1000242PubMedGoogle Scholar
  66. Kumagai T et al (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121(3):656–665PubMedGoogle Scholar
  67. Kumari A et al (2009) Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol 16(4):1051–1059PubMedGoogle Scholar
  68. Lachner M, Jenuwein T (2002) The many faces of histone lysine methylation. Curr Opin Cell Biol 14(3):286–298PubMedGoogle Scholar
  69. Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921PubMedGoogle Scholar
  70. Lee KH et al (2009) Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9(3):293–301PubMedGoogle Scholar
  71. Li A et al (2010a) Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors. Cancer Biol Ther 9(4):5226–5237Google Scholar
  72. Li A et al (2010b) Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 70(13):5226–5237PubMedGoogle Scholar
  73. Lim S et al (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31(3):512–520PubMedGoogle Scholar
  74. Lister R et al (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271):315–322PubMedGoogle Scholar
  75. Lohse B et al (2011) Inhibitors of histone demethylases. Bioorg Med Chem 19(12):3625–3636PubMedGoogle Scholar
  76. Lunter G, Hein J (2004) A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics 20(Suppl 1):i216–i223PubMedGoogle Scholar
  77. Matsubayashi H et al (2003) Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9(4):1446–1452PubMedGoogle Scholar
  78. Matsubayashi H et al (2006) DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 66(2):1208–1217PubMedGoogle Scholar
  79. Maunakea AK et al (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466(7303):253–257PubMedGoogle Scholar
  80. Md Zin R, Murch A, Charles A (2011) Pathology, genetics and cytogenetics of Wilms’ tumour. Pathology 43(4):302–312PubMedGoogle Scholar
  81. Mikkelsen TS et al (2007) Genome-wide maps of chromatin state in pluripotent and lineage-­committed cells. Nature 448(7153):553–560PubMedGoogle Scholar
  82. Ms K et al (2008) Gonadotrophin releasing hormone antagonist in IVF/ICSI. J Hum Reprod Sci 1(1):29–32PubMedGoogle Scholar
  83. Nakamura H (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Scientist 19(6):25–25Google Scholar
  84. Nakata B et al (2002) Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 8(8):2536–2540PubMedGoogle Scholar
  85. Nalls D et al (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6(8):e24099PubMedGoogle Scholar
  86. Nan X et al (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683):386–389PubMedGoogle Scholar
  87. O’Hagan HM et al (2011) Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20(5):606–619 Ohike N, Maass N et al (2003) Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 199(2):193–200PubMedGoogle Scholar
  88. Ohm JE et al (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39(2):237–242PubMedGoogle Scholar
  89. Okami J, Simeone DM, Logsdon CD (2004) Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 64(15):5338–5346PubMedGoogle Scholar
  90. Okano M, Xie SP, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19(3):219–220PubMedGoogle Scholar
  91. Okano M et al (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3):247–257PubMedGoogle Scholar
  92. Olson P et al (2009) MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23(18):2152–2165PubMedGoogle Scholar
  93. Omura N et al (2008) Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 7(7):1146–1156PubMedGoogle Scholar
  94. Ooi SK et al (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448(7154):714–717PubMedGoogle Scholar
  95. Ougolkov AV, Bilim VN, Billadeau DD (2008) Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14(21):6790–6796PubMedGoogle Scholar
  96. Parsi MA et al (2008) DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 6(11):1270–1278PubMedGoogle Scholar
  97. Peng L, Seto E (2011) Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 206:39–56PubMedGoogle Scholar
  98. Pili R et al (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106(1):77–84PubMedGoogle Scholar
  99. Rauch TA et al (2009) A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci USA 106(3):671–678PubMedGoogle Scholar
  100. Renaud S et al (2007) Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 35(4):1245–1256PubMedGoogle Scholar
  101. Robert MF et al (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33(1):61–65PubMedGoogle Scholar
  102. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1):19–25PubMedGoogle Scholar
  103. Rosty C et al (2002) Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 160(1):45–50PubMedGoogle Scholar
  104. Rosty C et al (2003) p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 27(12):1495–1501PubMedGoogle Scholar
  105. Ryu JK et al (2006) SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 237(1):143–154PubMedGoogle Scholar
  106. Ryu JK et al (2011) Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 11(3):343–350PubMedGoogle Scholar
  107. Saito Y et al (2006) Specific activation of microRNA-127 with downregulation of the proto-­oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9(6):435–443PubMedGoogle Scholar
  108. Sassen S, Miska EA, Caldas C (2008) MicroRNA: implications for cancer. Virchows Archiv 452(1):1–10PubMedGoogle Scholar
  109. Sato N, Fukushima N et al (2003a) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63(13):3735–3742PubMedGoogle Scholar
  110. Sato N, Fukushima N et al (2003b) SPARC/osteonectin is a frequent target for aberrant ­methylation in pancreaticadenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22(32):5021–5030PubMedGoogle Scholar
  111. Sato N et al (2004) Identification of maspin and S100P as novel hypomethylation targets in ­pancreatic cancer using global gene expression profiling. Oncogene 23(8):1531–1538PubMedGoogle Scholar
  112. Sato N et al (2005) Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24(5):850–858PubMedGoogle Scholar
  113. Sato N et al (2008) CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 21(3):238–244PubMedGoogle Scholar
  114. Sato F et al (2011) MicroRNAs and epigenetics. FEBS J 278(10):1598–1609PubMedGoogle Scholar
  115. Schildhaus HU et al (2011) Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol 42(11):1667–1675PubMedGoogle Scholar
  116. Schoeftner S et al (2006) Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J 25(13):3110–3122PubMedGoogle Scholar
  117. Schuebel KE et al (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3(9):1709–1723PubMedGoogle Scholar
  118. Schutte M et al (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57(15):3126–3130PubMedGoogle Scholar
  119. Shogren-Knaak M et al (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311(5762):844–847PubMedGoogle Scholar
  120. Siegel R et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedGoogle Scholar
  121. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29PubMedGoogle Scholar
  122. Song W et al (2010) Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101(7):1754–1760PubMedGoogle Scholar
  123. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403(6765):41–45PubMedGoogle Scholar
  124. Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99(6):3740–3745PubMedGoogle Scholar
  125. Thurman RE et al (2012) The accessible chromatin landscape of the human genome. Nature 489(7414):75–82PubMedGoogle Scholar
  126. Tonini T et al (2004) Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23(28):4930–4937PubMedGoogle Scholar
  127. Toyota M et al (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68(11):4123–4132PubMedGoogle Scholar
  128. Trojer P, Reinberg D (2006) Histone lysine demethylases and their impact on epigenetics. Cell 125(2):213–217PubMedGoogle Scholar
  129. Tsai H-C et al (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3):430–446PubMedGoogle Scholar
  130. Ueki T et al (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60(7):1835–1839PubMedGoogle Scholar
  131. Vincent A et al (2011) Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 17(13):4341–4354PubMedGoogle Scholar
  132. Vincenz C, Kerppola TK (2008) Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. Proc Natl Acad Sci USA 105(43):16572–16577PubMedGoogle Scholar
  133. Vire E et al (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078):871–874PubMedGoogle Scholar
  134. Wang L et al (2004) Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 14(5):637–646PubMedGoogle Scholar
  135. Wang W et al (2009a) Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. Oncol Rep 21(6):1439–1447PubMedGoogle Scholar
  136. Wang Y et al (2009b) LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4):660–672PubMedGoogle Scholar
  137. Winter JM et al (2008) Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 14(2):412–418PubMedGoogle Scholar
  138. Yamamoto H et al (2001) Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 61(7):3139–3144PubMedGoogle Scholar
  139. Yang XJ, Seto E (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37):5310–5318PubMedGoogle Scholar
  140. Yang H, Liu Y et al (2013) Tumor development is associated with decrease of TET gene expression and 5- methylcytosine hydroxylation. Oncogene 32(5):663–669 Yegnasubramanian S et al (2011) Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics 12:313PubMedGoogle Scholar
  141. Yen RW et al (1992) Isolation and characterization of the cDNA encoding human DNA ­methyltransferase. Nucleic Acids Res 20(9):2287–2291PubMedGoogle Scholar
  142. Yu J, Li A et al (2012a) MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18(4):981–992Google Scholar
  143. Yu J et al (2012b) MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18(4):981–992PubMedGoogle Scholar
  144. Zhang S et al (2011) Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 32(8):1183–1189PubMedGoogle Scholar
  145. Zhao XD et al (2007) Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 1(3):286–298PubMedGoogle Scholar
  146. Zinn RL et al (2007) hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67(1):194–201PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Department of Pathology, The Sol Goldman Pancreatic Cancer Research CenterJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Departments of Pathology, Medicine, and Oncology, The Sol Goldman Pancreatic Cancer Research CenterJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations